Cellular uptake of hydrophilic antifolates proceeds via the reduced folate carrier whereas lipophilic antifolates enter cells by diffusion. Recently we have shown that transfectant cells overexpressing the mutant G482 ABCG2 displayed 120-6,250-fold resistance to hydrophilic antifolates than untransfected cells upon 4 h drug exposure, but lost almost all their antifolate resistance upon 72 h drug exposure (Shafran et al. in Cancer Res 65:8414-8422, 2005). Here we explored the ability of the wild type (WT) R482-as well as the mutant G482-and T482 ABCG2 to confer resistance to lipophilic antifolate inhibitors of dihydrofolate reductase (trimetrexate, piritrexim, metoprine and pyrimethamine) and thymidylate synthase (AG337, AG377 and AG331). Lipophilic antifolate resistance was determined using growth inhibition assays upon 72 h drug exposure. Cells overexpressing these mutant efflux transporters displayed up to 106-fold resistance to lipophilic antifolates relative to untransfected cells; this resistance was reversed by the specific and potent ABCG2 efflux inhibitor Ko143. In contrast, cells overexpressing the WT R482 ABCG2 exhibited either no or only a low-level of lipophilic antifolate resistance. These results provide the first evidence that overexpression of the mutant G482- and T482 but not the WT R482 ABCG2 confers a high-level of resistance to lipophilic antifolates. The high membrane partitioning of lipophilic antifolates along with the large confinement of ABCG2 to the plasma membrane suggest that these mutant ABCG2 transporters may possibly recognize and extrude lipophilic antifolates from the lipid bilayer. The potential implications to cancer chemotherapy as well as the mechanism of anticancer drug extrusion by these mutant exporters are discussed.

01 Sep 2005·Molecular and Biochemical ParasitologyQ4 · MEDICINE

Differential drug binding by the highly conserved Plasmodium falciparum thymidylate synthase

Q4 · MEDICINE

Article

Author: Gabriele Varani ; Pradipsinh K. Rathod ; John White ; Surya Kanta De ; Frederick S. Buckner ; Cullen K.T. Pang

This study showed that small, lipophilic folate analogs AG337 and AG331, optimized to bind human thymidylate synthase (TS) at low nanomolar concentrations, bound Plasmodium TS 130-fold more weakly.Based on thermodn. principles, it should be possible to identify reciprocal small mols. that bind Plasmodium TS better than human TS.Data suggest that species-specific inhibitor design may be realized by exploiting subtle host-parasite differences in enzyme active-site conformations that are dictated by distant amino acids in the proteins.It is proposed that, in the absence of folate-derivatives, human and Plasmodium TS active sites exist in slightly different ground-state conformations.Upon meeting the full-length 5,10-methylenetetrahydrofolate substrate, or the full size inhibitor 1843U89, favorable interactions could provide sufficient intrinsic binding energy to both change the conformation of the enzymes to the catalytically active form and still maintain effective enzyme inhibition.

01 Jun 2004·Journal of Pharmaceutical and Biomedical AnalysisQ3 · MEDICINE

Development and validation of an HPLC method for AG331 bulk drug substance and lyophilized powder for injection

Q3 · MEDICINE

Article

Author: Praveen Tyle ; Wen-Chin Tsai ; Terry L Wilke

AG331 is a water soluble glucuronate salt of a novel antitumor compound synthesized by protein structure based drug design. A lyophilized powder for injection was developed for clinical studies. During HPLC assay development, AG331 showed an inherent tailing problem due to an amino group in the structure. An optimized reverse-phase gradient HPLC method was developed to minimize the tailing and separate AG331 from its synthetic intermediates (I-1, I-2, I-3, I-4, I-5, I-6, I-8), other impurities and degradation compounds. The method was shown to be linear, precise, accurate, rugged and stability-indicating.

100 Deals associated with Metesind glucuronate

External Link

KEGG	Wiki	ATC	Drug Bank
D04964	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Cancer	Phase 2	-	Pfizer Inc.	-
Brain Cancer	Phase 2	US	Agouron Pharmaceuticals LLC	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis